Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 17Filgrastim 6Daunorubicin 6tipifarnib 5Etoposide 5Clofarabine 5Idarubicin 4Gene Expression Profiling 4Gemtuzumab 4Cyclophosphamide 4Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Mitoxantrone 3Flow Cytometry 3Busulfan 3Arsenic Trioxide 3fludarabine phosphate 2aldesleukin 2Thiotepa 2Sorafenib 2Observation 2Melphalan 2Imatinib Mesylate 2Antilymphocyte Serum 2valspodar 1temsirolimus 1tanespimycin 1sargramostim 1romidepsin 1laromustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Basophilic, Acute × XK 469 × Clear all
NCT00095797 2013-02-08

XK469R in Treating Patients With Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡